Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2247 ARTÍCULOS , VIENDO DEL 2116 AL 2130

Exendin-4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease

Verma A, Chaudhary S, Solanki K, Goyal A, Yadav HN.

Chem Biol Drug Des. 2024 Jan;103(1):e14426. doi: 10.1111/cbdd.14426.

Modulation of Gut Microbiota Through Dietary Intervention in Neuroinflammation and Alzheimer's and Parkinson's Diseases

Ayten Ş, Bilici S.

Curr Nutr Rep. 2024 Jun;13(2):82-96. doi: 10.1007/s13668-024-00539-7. Epub 2024 Apr 23.

Photobiomodulation for Neurodegenerative Diseases: A Scoping Review

Shen Q, Guo H, Yan Y.

Int J Mol Sci. 2024 Jan 28;25(3):1625. doi: 10.3390/ijms25031625.

Methylsulfinyl Hexyl Isothiocyanate (6-MSITC) from Wasabi Is a Promising Candidate for the Treatment of Cancer, Alzheimer's Disease, and Obesity

Bartkowiak-Wieczorek J, Malesza M, Malesza I, Hadada T, Winkler-Galicki J, Grzelak T, Mądry E.

Nutrients. 2024 Aug 1;16(15):2509. doi: 10.3390/nu16152509.

Polyphenols Targeting NF-κB Pathway in Neurological Disorders: What We Know So Far?

Mamun AA, Shao C, Geng P, Wang S, Xiao J.

Int J Biol Sci. 2024 Jan 27;20(4):1332-1355. doi: 10.7150/ijbs.90982. eCollection 2024.

Research progress on the protection and mechanism of active peptides in Alzheimer's disease and Parkinson's disease

Ding X, Chen Y, Zhang X, Duan Y, Yuan G, Liu C.

Neuropeptides. 2024 Oct;107:102457. doi: 10.1016/j.npep.2024.102457. Epub 2024 Jul 25.

Characterization of de novo Dementia with Lewy Body with different duration of rapid eye movement sleep behavior disorder

Liu L, Shi Z, Gan J, Liu S, Wen C, Yang Y, Yang F, Ji Y.

Sleep Med. 2024 Feb;114:101-108. doi: 10.1016/j.sleep.2023.12.025. Epub 2023 Dec 26.

Rodent Models of Alzheimer's Disease: Past Misconceptions and Future Prospects

Collins HM, Greenfield S.

Int J Mol Sci. 2024 Jun 5;25(11):6222. doi: 10.3390/ijms25116222.

ApoE: The Non-Protagonist Actor in Neurological Diseases

Grimaldi L, Bovi E, Formisano R, Sancesario G.

Genes (Basel). 2024 Oct 30;15(11):1397. doi: 10.3390/genes15111397.

Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson's and Alzheimer's disease

McDowall S, Bagda V, Hodgetts S, Mastaglia F, Li D.

Transl Neurodegener. 2024 Dec 3;13(1):59. doi: 10.1186/s40035-024-00450-9.

Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?

Hölscher C.

Neuropharmacology. 2024 Aug 1;253:109952. doi: 10.1016/j.neuropharm.2024.109952. Epub 2024 Apr 25.

Gut microbiota defined epigenomes of Alzheimer's and Parkinson's diseases reveal novel targets for therapy

Nohesara S, Abdolmaleky HM, Thiagalingam S, Zhou JR.

Epigenomics. 2024 Jan;16(1):57-77. doi: 10.2217/epi-2023-0342. Epub 2023 Dec 13.

Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease

Hong CT, Chen JH, Hu CJ.

J Biomed Sci. 2024 Nov 5;31(1):102. doi: 10.1186/s12929-024-01090-x.

C/EBPβ: A transcription factor associated with the irreversible progression of Alzheimer's disease

Yao Q, Long C, Yi P, Zhang G, Wan W, Rao X, Ying J, Liang W, Hua F.

CNS Neurosci Ther. 2024 Apr;30(4):e14721. doi: 10.1111/cns.14721.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias